Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD3ɛ shRNA is a short hairpin RNA (shRNA) designed to silence the expression of the CD3 epsilon (CD3ɛ) subunit of the T-cell receptor (TCR) complex through RNA interference. In preclinical research, particularly involving ataxia-telangiectasia mutated (ATM) deficient models, it is utilized to investigate the dependency of thymic T-cell lymphomas on pre-TCR signaling. By knocking down CD3ɛ, the assembly and constitutive signaling of the pre-TCR are inhibited, which has been shown to significantly impair the survival of surface CD3ɛ-high (sRhi) lymphoma cells. This suggests that the pre-TCR signaling pathway is a critical survival requirement for certain subsets of T-cell acute lymphoblastic leukemia (T-ALL) and represents a potential target for clinical intervention.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CD3ɛ shRNA.